title: Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
authors.forename: Matthew
authors.initials: M
authors.lastname: Hotston
authors.forename: Nilima
authors.initials: N
authors.lastname: Shukla
authors.forename: Jonathon
authors.initials: J
authors.lastname: Bloor
authors.forename: Raj
authors.initials: R
authors.lastname: Persad
authors.forename: Jamie Y
authors.initials: JY
authors.lastname: Jeremy
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D053448:Prostatism / Q000188:drug therapy*
chemical_list: D010726:Phosphodiesterase Inhibitors; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human